Key Metrics

Market Cap	1.05B
Total Shares Outstanding	40.49M
Book Value	6.96
PE Ratio	-

PS Ratio	7.48
PB Ratio	3.72
Forward PE Ratio	116.28
ROIC	-

Return on Aseets	-9.19
Return on Equity	-12.43
Dividend	-
Dividend Yield	-

Balancesheet Metrics

Total Assets	318.56M
Total Liability	37.33M
Assets-to-Libability Ratio	8.53

Total Current Assets	293.82M
Total Current Liability	25.88M
Current Ratio	11.36

Quick Ratio	10.5
Debt to Equity Ratio	-

Income Statement Metrics

Net Income	-48.69M
EPS	-0.71
EBITA	-45.00M

Gross Profit	4.52M
Gross Profit Margin	-19.62%
Operating Margin	-21.46%

Net Profit Margin

-215.5%

Price Metrics

5 Days MA	25.47
10 Days MA	25.84
20 Days MA	27.68
50 Days MA	30.76
200 Days MA	45.01

52 Weeks High	66.54
52 Weeks low	24.64
All Time High	66.54

RSI	33.52
MACD	-

Share Stats

Shares Float	34.75M
Shares Short	2.41M

% Short	0.0676%
% Insider	5.056%

% Institutions	91.192%

% Institutions

91.192%

News

RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price TargetLast week, you might have seen that RxSight, Inc. (NASDAQ:RXST) released its annual result to the market. The early response was not positive, with shares down 7.0% to US$28.21 in the past week. Revenues came in at US$140m, in line with forecasts and the company reported a statutory loss of US$0.71 ...
Last week, you might have seen that RxSight, Inc. (NASDAQ:RXST) released its annual result to the market. The early response was not positive, with shares down 7.0% to US$28.21 in the past week. Revenues came in at US$140m, in line with forecasts and the company reported a statutory loss of US$0.71 per share, roughly in line with expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. View our latest analysis for RxSight NasdaqGM:RXST Earnings and Revenue Growth February 28th 2025 Taking into account the latest results, the current consensus from RxSight's ten analysts is for revenues of US$190.1m in 2025. This would reflect a substantial 36% increase on its revenue over the past 12 months. Losses are predicted to fall substantially, shrinking 21% to US$0.53. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$189.3m and losses of US$0.53 per share in 2025. The analysts trimmed their valuations, with the average price target falling 14% to US$44.80, with the ongoing losses seemingly weighing on sentiment, despite no real changes to the earnings forecasts. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic RxSight analyst has a price target of US$60.00 per share, while the most pessimistic values it at US$33.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business. Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's pretty clear that there is an expectation that RxSight's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 36% growth on an annualised basis. This is compared to a historical growth rate of 51% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 7.8% per year. So it's pretty clear that, while RxSight's revenue growth is expected to slow, it's still expected to grow faster than the industry itself. The Bottom Line The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of RxSight's future valuation. Story Continues Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple RxSight analysts - going out to 2027, and you can see them free on our platform here. And what about risks? Every company has them, and we've spotted 1 warning sign for RxSight you should know about. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments
RXST | finance.yahoo | about 17 days ago | Neutral

RxSight Full Year 2024 Earnings: EPS Beats ExpectationsRxSight (NASDAQ:RXST) Full Year 2024 Results Key Financial Results Revenue: US$139.9m (up 57% from FY 2023). Net loss: US$27.5m (loss narrowed by 44% from FY 2023). US$0.71 loss per share (improved from US$1.41 loss in FY 2023).NasdaqGM:RXST Earnings and Revenue Growth February 27th 2025 All figu...

RXST | finance.yahoo | about 18 days ago | Neutral

RxSight Inc (RXST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...Revenue: $40.2 million in Q4 2024, up 41% year-over-year. LAL Revenue: $28.5 million in Q4 2024, up 60% year-over-year. LDD Revenue: $10.7 million in Q4 2024. Gross Margin: 71.6% in Q4 2024, up from 61.8% in Q4 2023. SG&A Expenses: $28.2 million in Q4 2024, up 33% year-over-year. R&D Expenses: $9.2 ...
Revenue: $40.2 million in Q4 2024, up 41% year-over-year. LAL Revenue: $28.5 million in Q4 2024, up 60% year-over-year. LDD Revenue: $10.7 million in Q4 2024. Gross Margin: 71.6% in Q4 2024, up from 61.8% in Q4 2023. SG&A Expenses: $28.2 million in Q4 2024, up 33% year-over-year. R&D Expenses: $9.2 million in Q4 2024, up 25% year-over-year. Net Loss: $5.9 million in Q4 2024, or $0.15 per share. Adjusted Net Income: $1.3 million or $0.03 per share in Q4 2024. Cash and Equivalents: $237.2 million at year-end 2024. 2025 Revenue Guidance: $185 million to $197 million, growth of 32% to 41%. 2025 Gross Margin Guidance: 71% to 73%. 2025 Operating Expenses Guidance: $165 million to $170 million. Warning! GuruFocus has detected 2 Warning Sign with PRCT. Release Date: February 25, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points RxSight Inc (NASDAQ:RXST) reported a 41% increase in revenue for Q4 2024 compared to the same quarter in the previous year, driven by strong growth in LAL procedure volume. The company achieved a record sale of 2,969 LALs in Q4 2024, marking a 61% increase from Q4 2023. Gross margin expanded to 71.6% in Q4 2024, up from 61.8% in Q4 2023, due to a favorable revenue mix and lower manufacturing costs. RxSight Inc (NASDAQ:RXST) ended 2024 with no debt and $237.2 million in cash equivalents and short-term investments. The company received FDA approval for additional LDD functionality, enhancing customization options for cataract surgery, which is expected to be released in the second half of 2025. Negative Points RxSight Inc (NASDAQ:RXST) reported a net loss of $5.9 million in Q4 2024, although this was an improvement from the $9.2 million loss in Q4 2023. SG&A expenses increased by 33% year-over-year in Q4 2024, primarily due to higher sales and clinical personnel costs. Research and development expenses rose by 25% year-over-year in Q4 2024, driven by increased facility costs and stock-based compensation. Revenue contribution from outside North America is expected to remain nominal in 2025, with more meaningful impact anticipated in 2026 and beyond. The company anticipates operating expenses to increase by 22% to 25% in 2025, reflecting ongoing investments in sales, marketing, and R&D. Q & A Highlights Q: How do you see LAL utilization trends evolving in 2025, and how does utilization vary between mature and newer accounts? A: Shelley Thunen, CFO, explained that LAL utilization is influenced by the installed base of LDDs and the number of LALs implanted. Utilization can fluctuate due to seasonality and the mix of newer LDDs. However, cohorts of LDD installs from previous years show consistent growth, with no ceiling observed. The focus remains on driving more LALs through increased LDDs and adoption within accounts. Story Continues Q: Can you elaborate on the potential of the new Aspheric IOL functionality and its target patient demographic? A: Ron Kurtz, CEO, clarified that both LAL and LAL Plus are already aspheric lenses. The new LDD functionality allows doctors to modify the level of asphericity, which can be advantageous for different patient populations. This advancement opens the door for higher customization in cataract surgery, similar to corneal refractive surgery advancements. Q: What are the main areas of focus for growth investments in 2025, particularly in the commercial organization and marketing? A: Ron Kurtz, CEO, stated that the focus is on clinical training, field support, and education within practices and the wider eye care community, including optometry. Shelley Thunen, CFO, added that the commercial organization has expanded significantly to support new and existing customers, with a goal to capture a larger share of the premium IOL market. Q: How should we think about the cadence for gross margin and spending in 2025, and the mix between LDD and LAL? A: Shelley Thunen, CFO, indicated that LAL is expected to grow faster and become a more predominant portion of revenue, leading to margin expansion. While LDD sales are not held back to manage gross margin, the mix will determine quarterly margins. The company expects consistent gross margin improvements, with potential to reach 80% plus at maturity. Q: What gives you confidence in maintaining or accelerating LAL utilization growth in 2025? A: Shelley Thunen, CFO, emphasized that the key metric is the absolute number of LALs implanted. The company expects steady growth consistent with revenue expectations, and while LALs per LDD may vary quarterly, the overall trend is positive. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
RXST | finance.yahoo | about 19 days ago | Neutral

RxSight, Inc. (RXST) Misses Q4 Earnings EstimatesRxSight, Inc. (RXST) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -70%. ...
RxSight, Inc. (RXST) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -70%. A quarter ago, it was expected that this company would post earnings of $0.02 per share when it actually produced break-even earnings, delivering a surprise of -100%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. RxSight , which belongs to the Zacks Medical - Instruments industry, posted revenues of $40.21 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.07%. This compares to year-ago revenues of $28.58 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. RxSight shares have lost about 14.8% since the beginning of the year versus the S&P 500's gain of 1.7%. What's Next for RxSight? While RxSight has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for RxSight: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.01 on $40.64 million in revenues for the coming quarter and $0.27 on $190.95 million in revenues for the current fiscal year. Story Continues Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, OrthoPediatrics (KIDS), has yet to report results for the quarter ended December 2024. The results are expected to be released on March 4. This maker of orthopedic devices is expected to post quarterly loss of $0.22 per share in its upcoming report, which represents a year-over-year change of +4.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. OrthoPediatrics' revenues are expected to be $52.7 million, up 40.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report RxSight, Inc. (RXST) : Free Stock Analysis Report OrthoPediatrics Corp. (KIDS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
RXST | finance.yahoo | about 19 days ago | Neutral

RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 GuidanceRxSight, Inc. ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results for the three months and full-year ended December ...
RxSight, Inc. ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results for the three months and full-year ended December 31, 2024. Key Quarterly and Full-Year Highlights Recognized fourth quarter 2024 revenue of $40.2 million, an increase of 41% compared to the fourth quarter of 2023, reflecting: The sale of 29,069 Light Adjustable Lenses (LAL™/LAL+®), representing an 61% increase in procedure volume compared to the fourth quarter of 2023; and The sale of 83 Light Delivery Devices (LDD™s), expanding the installed base to 971 LDDs at the end of the quarter, a 46% increase compared to the 666-unit LDD installed base at the end of the fourth quarter of 2023. Recognized full-year 2024 revenue of $139.9 million, a 57% increase over 2023, driven by unit sales of 98,055 LALs and 305 LDDs, representing growth of 79% and 15% respectively, compared to 2023. “The progress we’ve made over the past year has strengthened our conviction that adjustability has the potential to transform the premium cataract market, and that we are still in the early stages of realizing this vision,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. “As we look ahead to 2025 and beyond, we are excited by the opportunity to further expand adoption globally, advance our technology, and continue delivering exceptional outcomes for both patients and practices.” Fourth Quarter Financial Results In the fourth quarter of 2024, total revenue was $40.2 million, an increase of 41% compared to $28.6 million in the fourth quarter of 2023. Revenue growth was driven by a 60% increase in LAL revenue and a 7% increase in LDD revenue, compared to the fourth quarter of 2023. Gross profit for the fourth quarter of 2024 was $28.8 million or 71.6% of revenue, an increase of $11.1 million compared to gross profit of $17.7 million or 61.8% of revenue for the fourth quarter of 2023. The year over year increase in gross profit was driven by continued growth in the percentage of LAL sales as a proportion of total sales, lower cost of sales for both the LDD and LAL, and sustained pricing stability for company’s capital equipment. Total operating expenses for the fourth quarter of 2024 were $37.4 million, a 31% increase from $28.5 million in the fourth quarter of 2023, on an increase in revenue of 41%, reflecting the company’s ongoing investments to grow its LDD installed base and support increased LAL sales volume while managing the company’s operating expenses. Story Continues In the fourth quarter of 2024, the company reported a net loss of $(5.9) million, or $(0.15) per basic and diluted share, compared to a net loss of $(9.2) million, or $(0.26) per basic and diluted share in the fourth quarter of 2023. Adjusted net earnings in the fourth quarter of 2024 were $1.3 million, or $0.03 per basic and diluted share, compared to an adjusted net loss of $(4.8) million, or $(0.13) per basic and diluted share in the fourth quarter of 2023. Cash, cash equivalents and short-term investments as of December 31, 2024, were $237.2 million. Fiscal Year 2024 Financial Results Full-year 2024 total revenue was $139.9 million, an increase of 57% compared to the full year of 2023. The increase in 2024 revenue was driven by a 78% increase in LAL revenue and 24% increase in LDD revenue compared to 2023. Gross profit for the full year of 2024 was $98.9 million, or 70.7% of revenue compared to gross profit of $53.8 million, or 60.4% of revenue for the full year of 2023. The increase in gross profit was due to a favorable product mix from a greater percentage of revenue from LAL sales and increased margins on the LDD introduced during the third quarter of 2023. Total operating expenses for the full year of 2024 were $135.8 million, a 31% increase from $103.9 million for the full year of 2023. The increase was primarily driven by a higher headcount in sales and marketing to support the growth of the business, costs of operating as a public company and an operating expense increase of $8.0 million in non-cash stock-based compensation expense. In 2024, net loss was $(27.5) million, or $(0.71) per share on a basic and diluted basis compared to a net loss of $(48.6) million, or $(1.41) per share on a basic and diluted basis in 2023. Adjusted net loss was $(2.8) million, or $(0.07) per share on a basic and diluted basis, in 2024, compared to an adjusted net loss of $(31.1) million, or $(0.90) per share on a basic and diluted basis in 2023. 2025 Guidance The company is reiterating guidance for the full-year 2025 revenue, gross profit margin, and operating expenses: Revenue in the range of $185.0 million to $197.0 million, representing implied growth of approximately 32% to 41% compared to 2024; Gross margin in the range of 71% to 73%, representing an implied increase of 30 bps to 230 bps compared to 2024; Operating expenses in the range of $165.0 to $170.0 million, representing an implied increase of 22% to 25% compared to 2024; Operating expense guidance also includes non-cash expenses in the range of $22.0 million to $25.0 million. Conference Call On Tuesday, February 25, 2025, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its fourth quarter 2024 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 7159871. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com. Forward-Looking Statements This press release contains forward-looking statements, including: management’s view that adjustability has the potential to transform the premium cataract market; LDD and LAL sales growth trends; the Company’s plans to expand adoption globally and advance its technology; the Company’s expectation of continuing to deliver exceptional outcomes for both patients and practices; and the Company’s projected revenue, gross margin and operating expenses in 2025. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part I, Item 1A (Risk Factors) in the Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that the Company may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law. Company Contact: Shelley B. Thunen Chief Financial Officer sthunen@rxsight.com Investor Relations Contact: Oliver Moravcevic VP, Investor Relations omoravcevic@rxsight.com RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (In thousands, except share and per share amounts) Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 Sales $ 40,214 $ 28,580 $ 139,927 $ 89,077 Cost of sales 11,426 10,925 40,984 35,312 Gross profit 28,788 17,655 98,943 53,765 Operating expenses: Selling, general and administrative 28,209 21,165 101,434 74,799 Research and development 9,208 7,341 34,367 29,051 Total operating expenses 37,417 28,506 135,801 103,850 Loss from operations (8,629 ) (10,851 ) (36,858 ) (50,085 ) Other income (expense), net: Interest expense (5 ) (4 ) (21 ) (3,308 ) Interest and other income 2,708 1,661 9,474 6,574 Loss on extinguishment of term loan — — — (1,769 ) Loss before income taxes (5,926 ) (9,194 ) (27,405 ) (48,588 ) Income tax expense 12 (18 ) 50 20 Net loss $ (5,938 ) $ (9,176 ) $ (27,455 ) $ (48,608 ) Other comprehensive (loss) income Unrealized (loss) gain on short-term investments (344 ) 46 180 83 Foreign currency translation (loss) gain (12 ) 4 (9 ) 7 Total other comprehensive (loss) income (356 ) 50 171 90 Comprehensive loss $ (6,294 ) $ (9,126 ) $ (27,284 ) $ (48,518 ) Net loss per share: Basic and diluted $ (0.15 ) $ (0.26 ) $ (0.71 ) $ (1.41 ) Weighted-average shares used in computing net loss per share: Attributable to common stock, basic and diluted 40,356,756 35,961,894 38,867,726 34,455,111 RxSIGHT, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share amounts) December 31, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 16,706 $ 9,692 Short-term investments 220,517 117,490 Accounts receivable 30,050 20,281 Inventories, net 22,009 17,421 Prepaid and other current assets 4,541 3,523 Total current assets 293,823 168,407 Property and equipment, net 12,413 10,841 Operating leases right-of-use assets 11,217 2,444 Restricted cash 750 711 Other assets 360 147 Total assets $ 318,563 $ 182,550 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 4,544 $ 3,863 Accrued expenses and other current liabilities 20,358 15,239 Lease liabilities 974 1,801 Total current liabilities 25,876 20,903 Long-term lease liabilities 11,322 1,211 Other long-term liabilities 127 74 Total liabilities 37,325 22,188 Commitments and contingencies Stockholders' equity: Common stock, $0.001 par value, 900,000,000 shares authorized, 40,428,220 shares issued and outstanding as of December 31, 2024 and 36,139,513 shares issued and outstanding as of December 31, 2023 40 36 Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding — — Additional paid-in capital 903,127 754,971 Accumulated other comprehensive loss 166 (5 ) Accumulated deficit (622,095 ) (594,640 ) Total stockholders' equity 281,238 160,362 Total liabilities and stockholders' equity $ 318,563 $ 182,550 Non-GAAP Financial Measures To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including adjusted net earnings (loss), and adjusted net earnings (loss) per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense and loss on extinguishment of term loan because these expenses are non-cash in nature and we believe excluding these items provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business. Adjusted Net Earnings (Loss) and Adjusted Net Earnings (Loss) Per Share Adjusted net earnings (loss) is a non-GAAP financial measure that we define as net earnings (loss) adjusted for (i) stock-based compensation and (ii) loss on extinguishment of term loan. We believe adjusted net earnings (loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. Reconciliations of net earnings (loss) to adjusted net earnings (loss) and the presentation of adjusted net earnings (loss) per share, basic and diluted, are as follows: RxSIGHT, INC. GAAP To NON-GAAP RECONCILIATIONS (UNAUDITED) (In thousands, except share and per share amounts) Three months ended December 31, Year ended December 31, 2024 2023 2024 2023 Common Stock Numerator: Net loss available to stockholders, basic and diluted $ (5,938 ) $ (9,176 ) $ (27,455 ) $ (48,608 ) Add: Stock-based compensation 7,282 4,425 24,635 15,746 Loss on extinguishment of term loan — — — 1,769 Adjusted net income (loss) available to common stockholders, basic and diluted: $ 1,344 $ (4,751 ) $ (2,820 ) $ (31,093 ) Denominator: Weighted-average shares outstanding, basic 40,356,756 35,961,894 38,867,726 34,455,111 Weighted-average shares outstanding, diluted 45,622,429 35,961,894 38,867,726 34,455,111 Adjusted net earnings (loss) per share, basic $ 0.03 $ (0.13 ) $ (0.07 ) $ (0.90 ) Adjusted net earnings (loss) per share, diluted $ 0.03 $ (0.13 ) $ (0.07 ) $ (0.90 ) View Comments
RXST | finance.yahoo | about 20 days ago | Neutral

RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025RxSight, Inc. ALISO VIEJO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter of 2024...

RXST | finance.yahoo | about 2 months ago | Neutral

Insider Stock Buying Reaches US$1.83m On RxSightMultiple insiders secured a larger position in RxSight, Inc. (NASDAQ:RXST) shares over the last 12 months. This is reassuring as this suggests that insiders have increased optimism about the company's prospects. Although we don't think shareholders should simply follow insider transactions, we do t...
Multiple insiders secured a larger position in RxSight, Inc. (NASDAQ:RXST) shares over the last 12 months. This is reassuring as this suggests that insiders have increased optimism about the company's prospects. Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing. See our latest analysis for RxSight RxSight Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider purchase was by Independent Chairman of the Board Jesse Corley for US$1.0m worth of shares, at about US$45.37 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$33.87). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Happily, we note that in the last year insiders paid US$1.8m for 38.69k shares. But they sold 9.13k shares for US$429k. In the last twelve months there was more buying than selling by RxSight insiders. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!NasdaqGM:RXST Insider Trading Volume February 2nd 2025 RxSight is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this freelist of growing companies with recent insider purchasing, could be just the ticket. RxSight Insiders Bought Stock Recently Over the last three months, we've seen significant insider buying at RxSight. We can see that Independent Chairman of the Board Jesse Corley paid US$1.1m for shares in the company. No-one sold. This makes one think the business has some good points. Insider Ownership Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. RxSight insiders own about US$68m worth of shares. That equates to 5.0% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders. Story Continues What Might The Insider Transactions At RxSight Tell Us? The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of RxSight we think they are probably pretty confident of a bright future. Therefore, you should definitely take a look at this FREEreport showing analyst forecasts for RxSight. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this freelist of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments
RXST | finance.yahoo | about 2 months ago | Neutral

RxSight price target lowered to $43 from $66 at Needhamhttps://www.tipranks.com/news/the-fly/irhythm-price-target-raised-to-125-from-112-at-needham Needham lowered the firm’s price target on RxSight (RXST) to $43 from $66 and keeps a Buy rating on the shares as part of a broader research note on MedTech/Diagnostics sector. Following the recent pre-anno...

RXST | finance.yahoo | about 2 months ago | Neutral

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 GuidanceRxSight, Inc. ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operati...
RxSight, Inc. ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance. Preliminary Unaudited Fourth Quarter and Full-year 2024 Results Preliminary unaudited fourth quarter 2024 revenue is expected to be approximately $40.2 million, representing growth of approximately 41% compared to the prior year period, driven by: The sale of 29,069 Light Adjustable Lenses (LAL™/LAL+®); representing a 61% increase in procedure volume compared to the fourth quarter of 2023; and The sale of 83 Light Delivery Devices (LDD™s), expanding the installed base to 971 LDDs as of December 31, 2024, representing a 46% increase compared to the installed base at end of the fourth quarter of 2023. Preliminary unaudited 2024 fiscal year revenue is expected to be approximately $139.9 million, representing growth of approximately 57% compared to the prior year, driven by: The sale of 98,055 LALs; representing a 79% increase in procedure volume compared to 2023; and The sale of 305 LDDs. Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2024, is expected to be $237.2 million. “During the fourth quarter, we achieved record highs for LDD sales and LAL procedures, meaningfully exceeding our initial full-year 2024 revenue guidance. With nearly one thousand LDDs installed, we now serve an estimated 15% of cataract surgeons in North America, while LAL procedures account for over 10% of the region’s premium IOL market. We believe this sustained growth in one of ophthalmology’s most competitive segments reflects the growing recognition of the superior visual outcomes enabled by adjustability,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. “In 2025, we expect adoption for the RxSight system to remain strong as we collaborate with a diverse range of customers to further expand the infrastructure for post-operative light treatments. Building on our momentum in North America, we also look forward to entering key international markets in Asia and Europe. Finally, leveraging the foundation established since our initial FDA approval, we plan to continue to innovate the RxSight system, that we believe will continue to set the standard for the premium IOL market for years to come.” 2025 Guidance RxSight anticipates full-year 2025 revenue in the range of $185.0 million to $197.0 million, reflecting growth of approximately 32% to 41% over 2024. The company currently estimates the full-year 2025 gross profit margin to be in the 71% to 73% range. In addition, the company expects full-year 2025 operating expenses in the range of $165.0 million to $170.0 million, including non-cash stock-based compensation expense guidance in the range of $22.0 million to $25.0 million. Story Continues The Company’s fourth quarter and full-year 2024 financial and operational results are preliminary and are subject to the completion of the Company’s 2024 audit. Audited full-year 2024 and unaudited fourth quarter 2024 financial results are expected to be announced in February 2025. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com. Forward-Looking Statements This press release contains forward-looking statements, including: statements concerning: the growing recognition of superior outcomes enabled by adjustability; the Company’s preliminary unaudited fourth quarter and fiscal 2024 financial and operational results and the anticipated timing of announcing audited full-year 2024 and unaudited fourth quarter 2024 financial results; the expectation of strong adoption for the RxSight system; the Company’s plans to enter international markets; the Company’s plans to continue innovating the RxSight system, that it believes will set the standard for the premium IOL market for the years to come; the potential of the Company’s technology and management’s plans related thereto; and the Company’s projected revenue, gross profit margin, operating expenses and non-cash expenses in 2025. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including in Part II, Item 1A (Risk Factors) of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 7, 2024, and any subsequent filings with the SEC. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law. The foregoing financial and operational results are preliminary estimates. We are in the process of finalizing our financial statements for the year ended December 31, 2024, and our actual results remain subject to completion of those financial statements and their audit by our independent registered public accounting firm. These preliminary estimates are based on information available to management as of the date of this press release and certain related assumptions, which could prove incorrect. Our actual, reported results of operations could differ based on completion of our year end closing procedures, final adjustments and developments that may arise prior to completion of our annual financial statements, and adjustments arising from the audit by our independent registered public accounting firm. You should carefully review our audited, consolidated financial statements for the year ended December 31, 2024 when they become available. Company contact: Shelley B. Thunen Chief Financial Officer sthunen@rxsight.com Investor Relations Contact: Oliver Moravcevic VP, Investor Relations omoravcevic@rxsight.com View Comments
RXST | finance.yahoo | about 3 months ago | Neutral

RxSight, Inc. to Present at the J.P. Morgan Healthcare ConferenceRxSight, Inc. ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan He...

RXST | finance.yahoo | about 3 months ago | Neutral

Profile

Rxsight Inc (RXST)

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Exchange: NASDAQ

IPO Date: 7/30/2021

Sector: Healthcare

Industry: Medical Devices

Employees: 498

Address: 100 Columbia, Aliso Viejo, CA, United States, 92656

https://www.rxsight.com

Quarterly Yearly

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2024	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023	12/31/2022	09/30/2022	Totals
	12/31/2024	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023	12/31/2022	09/30/2022	Totals
Assets	318.56K	310.47K	305.50K	183.16K	182.55K	181.85K	195.26K	202.53K	150.16K	155.71K	3.22M
Current Assets	293.82K	286.77K	281.22K	168.56K	168.41K	167.95K	180.44K	187.67K	134.56K	139.16K	2.92M
Cash And Short Term Investments	237.22K	237.12K	233.28K	125.35K	127.18K	131.88K	147.09K	153.94K	105.80K	112.83K	2.34M
Net Receivables	30.05K	25.37K	25.72K	21.55K	20.28K	15.24K	13.29K	12.67K	10.96K	9.02K	214.95K
Inventory	22.01K	21.67K	19.44K	18.70K	17.42K	18.92K	17.95K	18.07K	14.84K	15.34K	248.53K
Other Current Assets	4.54K	2.61K	2.77K	2.96K	3.52K	1.90K	2.11K	2.99K	2.96K	1.97K	45.44K
Non Current Assets	24.74K	23.70K	24.28K	14.61K	14.14K	13.90K	14.82K	14.87K	15.61K	16.54K	300.69K
Property Plant Equipment	-	-	-	-	-	-	13.71K	9.80K	10.14K	10.62K	124.74K
Long Term Investments	-	-	-	-	-	-	-	-	-	-	-
Non Currrent Assets Other	1.11K	924	303	226	147	137	348	746	1.53K	1.59K	18.57K
Liabilities	37.33K	33.21K	30.29K	19.24K	22.19K	20.37K	38.07K	57.52K	60.26K	59.75K	1.45M
Current Liabilities	25.88K	22.64K	19.62K	18.33K	20.90K	18.94K	16.57K	14.88K	17.24K	16.37K	264.82K
Accounts Payable	4.54K	4.58K	5.09K	5.06K	3.86K	4.11K	4.00K	3.72K	2.60K	4.17K	61.09K
Short Long Term Debt	-	-	-	-	-	-	-	-	-	-	-
Other Current Liabilities	17.25K	18.06K	13.05K	10.04K	13.19K	12.86K	10.59K	9.18K	11.32K	10.25K	165.44K
Non Current Liabilities	11.45K	10.57K	10.67K	908	1.28K	1.43K	21.51K	42.65K	43.02K	43.38K	1.18M
Long Term Debt	-	-	-	-	-	-	-	42.65K	-	43.38K	303.95K
Other Liabilities	-	-	-	-	-	-	76	-	-	-	3.90K
Stockholder Equity	281.24K	277.26K	275.21K	163.93K	160.36K	161.48K	157.19K	145.01K	89.90K	95.96K	1.42M
Preferred Stock Equity	-	-	-	-	-	-	-	-	-	-	-
Liabilities And Stockholders Equity	318.56K	310.47K	305.50K	183.16K	182.55K	181.85K	195.26K	202.53K	150.16K	155.71K	3.12M
Common Equity	-	-	-	-	-	-	-	34	28	28	206
Retained Earnings	-	-	-	-	-	-	-	-559.24K	-546.03K	-530.42K	-4.04M
Totals		1.63M	1.59M	1.55M	935.78K	938.00K	932.82K	1.03M	562.20K	275.05K	361.35K	431.61K	490.54K	586.88K	654.82K	-221.14K	889.02K	718.91K	-	-	13.35M

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	Totals
	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	Totals
Assets	318.56K	182.55K	150.16K	192.72K	100.68K	110.43K	1.06M
Current Assets	293.82K	168.41K	134.56K	176.29K	81.50K	90.20K	944.78K
Cash And Short Term Investments	237.22K	127.18K	105.80K	159.33K	68.97K	80.67K	779.18K
Net Receivables	30.05K	20.28K	10.96K	4.86K	2.87K	789	69.80K
Inventory	22.01K	17.42K	14.84K	8.03K	8.29K	7.22K	77.80K
Other Current Assets	4.54K	3.52K	2.96K	8.14K	1.37K	1.52K	22.06K
Non Current Assets	24.74K	14.14K	15.61K	16.43K	19.18K	20.23K	110.33K
Property Plant Equipment	-	-	10.14K	11.22K	18.61K	19.25K	59.21K
Long Term Investments	-	-	-	-	-	-	-
Non Currrent Assets Other	1.11K	147	767	114	110	983	3.23K
Liabilities	37.33K	22.19K	60.26K	54.48K	398.21K	415.04K	987.50K
Current Liabilities	25.88K	20.90K	17.24K	11.08K	11.60K	8.46K	95.15K
Accounts Payable	4.54K	3.86K	2.60K	1.69K	1.13K	2.20K	16.02K
Short Long Term Debt	-	-	-	-	-	-	-
Other Current Liabilities	17.25K	13.19K	9.35K	5.71K	9.19K	4.89K	59.59K
Non Current Liabilities	11.45K	1.28K	43.02K	43.40K	386.61K	406.59K	892.35K
Long Term Debt	-	-	-	43.40K	-	-	43.40K
Other Liabilities	-	-	-	-	136.89K	189.68K	326.57K
Stockholder Equity	281.24K	160.36K	89.90K	138.24K	-297.53K	-304.61K	67.60K
Preferred Stock Equity	-	-	-	-	-	-	-
Liabilities And Stockholders Equity	318.56K	182.55K	150.16K	192.72K	100.68K	110.43K	1.06M
Common Equity	-	-	28	27	80.78K	56.42K	137.26K
Retained Earnings	-	-	-546.03K	-479.28K	-	-	-1.03M
Totals		1.63M	938.00K	272.32K	588.61K	1.13M	1.22M	5.78M

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	06/30/2022	03/31/2022	12/31/2021	09/30/2021	06/30/2021	03/31/2021	12/31/2020	09/30/2020	06/30/2020	03/31/2020	Totals
	06/30/2022	03/31/2022	12/31/2021	09/30/2021	06/30/2021	03/31/2021	12/31/2020	09/30/2020	06/30/2020	03/31/2020	Totals
Revenue	11.36K	8.94K	8.43K	5.79K	4.90K	3.48K	4.91K	4.17K	2.71K	2.89K	57.57K
Cost Of Revenue	6.57K	5.18K	5.56K	4.45K	5.71K	2.37K	3.53K	3.45K	3.18K	2.81K	42.80K
Gross Profit	4.79K	3.76K	2.87K	1.34K	-812	1.12K	1.38K	720	-474	78	14.77K
Operating Expenses	20.58K	20.34K	17.53K	14.45K	13.06K	12.25K	13.21K	9.63K	11.51K	9.47K	142.05K
Selling General Administrative	14.39K	13.62K	11.62K	9.08K	6.50K	5.61K	4.40K	3.83K	3.25K	-	72.29K
Research Development	6.19K	6.72K	5.92K	5.38K	6.56K	6.64K	5.27K	5.80K	5.08K	5.78K	59.34K
Other Operating Expenses	27.15K	25.52K	23.09K	18.90K	-	14.62K	-	13.08K	-	12.29K	134.64K
Operating Income	-15.79K	-16.58K	-14.66K	-13.11K	-13.88K	-11.13K	-8.29K	-8.91K	-8.81K	-9.40K	-120.56K
Net Interest Income	-940	-1.01K	-1.07K	-1.07K	-811	-681	-477	60	143	-	-5.86K
Interest Income	196	46	10	11	15	17	21	63	147	-	526
Interest Expense	1.14K	1.06K	1.08K	1.08K	826	698	498	3	4	5	6.39K
Other Income Expense Net	-940	-1.01K	-1.07K	435	1.21K	4.34K	35.07K	39.58K	-4.18K	-7.10K	66.33K
Income Before Tax	-16.73K	-17.59K	-15.73K	-12.68K	-13.47K	-6.80K	26.30K	30.67K	-12.84K	-16.50K	-55.37K
Tax Provision	-	4	2	-4	3	7	4	8	40	-	64
NetIncome	-16.73K	-17.60K	-15.73K	-12.67K	-13.48K	-6.80K	26.30K	30.66K	-12.88K	-16.50K	-55.44K
NetIncome Applicable To Common Shares	-16.73K	-17.60K	-15.73K	-12.67K	-13.48K	-6.80K	-	5.90K	-16.98K	-20.75K	-114.84K
Ebit	-15.60K	-16.53K	-14.65K	-11.60K	-12.65K	-6.10K	-	30.68K	-8.81K	-16.49K	-71.75K
Basic EPS	-	-0.64	-0.58	-0.68	-0.51	-	-1.7	-	-	-	-4.11
Totals		8.90K	-2.73K	-2.56K	-2.90K	-29.78K	12.83K	112.13K	169.38K	-38.90K	-53.42K	172.94K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2021	12/31/2020	12/31/2019	Totals
	12/31/2021	12/31/2020	12/31/2019	Totals
Revenue	22.59K	14.68K	2.24K	39.51K
Cost Of Revenue	18.08K	12.97K	4.06K	35.11K
Gross Profit	4.52K	1.71K	-1.82K	4.40K
Operating Expenses	57.30K	37.11K	44.77K	139.19K
Selling General Administrative	32.80K	15.18K	15.20K	63.18K
Research Development	24.50K	21.93K	29.57K	76.00K
Other Operating Expenses	75.38K	50.08K	48.83K	174.29K
Operating Income	-52.79K	-35.41K	-46.07K	-134.27K
Net Interest Income	-3.63K	33	2.28K	-1.31K
Interest Income	54	543	2.31K	2.90K
Interest Expense	3.68K	510	26	4.22K
Other Income Expense Net	4.11K	63.04K	172.31K	239.47K
Income Before Tax	-48.68K	27.63K	126.24K	105.20K
Tax Provision	8	57	24	89
NetIncome	-48.69K	27.57K	126.22K	105.11K
NetIncome Applicable To Common Shares	-48.69K	3.37K	26.13K	-19.20K
Ebit	-45.00K	28.14K	126.27K	109.41K
Basic EPS	-1.77	-1.7	-	-3.4699999999999998
Totals		-4.45K	269.15K	678.60K	943.30K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2024	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023	12/31/2022	09/30/2022	Totals
	12/31/2024	09/30/2024	06/30/2024	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023	12/31/2022	09/30/2022	Totals
Cash From Operating Activities	-4.26K	650	-4.11K	-9.31K	-9.89K	-7.98K	-7.55K	-17.76K	-13.85K	-15.19K	-198.97K
Net Income	-5.94K	-6.34K	-6.08K	-9.10K	-9.18K	-12.41K	-13.80K	-13.21K	-15.61K	-16.82K	-163.93K
Depreciation	523	1.14K	820	1.14K	1.08K	1.13K	1.03K	999	961	980	19.89K
Extraordinary Items	-	-	-	-	-	-	-	-	-	-	-
Change Receivables	-	-	-	-	-	-	-	-1.71K	-1.94K	-2.14K	-7.81K
Change To Inventory	-408	-2.40K	-799	-1.39K	1.35K	-977	117	-3.24K	203	-4.05K	-18.71K
Change To Liabilities	-	-	-	-	-	-	-	-2.33K	730	3.35K	1.61K
Change To Net Income	-	-	-	-	-	-	-	3.31K	3.26K	3.22K	-7.94K
ChangeToOperatingActivities	-	-	-	-	-	-	-	2.81K	-	2.88K	4.98K
Cash flows From Investing Activities	-	-	-	-	-	-	-	-48.37K	10.40K	560	-60.22K
Capital Expenditures	-847	-1.10K	-1.52K	-1.97K	-1.59K	-653	-1.82K	-747	-362	-580	-17.13K
Other Cashflows From Investing Activities	-	-	-	-	-	-	-	-	-	-	-
Cash From Financing Activities	2.98K	878	111.55K	7.99K	5.15K	-8.23K	891	65.31K	6.31K	-455	355.42K
Net Borrowings	-	-	-	-	-	-	-	-20.04K	-1	-2	-5.26K
Sale Purchase Of Stock	-	2.13K	1	-	-2	-1.08K	-	-337	-1.48K	-150	124
Dividends Paid	-	-	-	-	-	1.08K	-	337	-	-	1.42K
Other Cashflows From Financing Activities	-	889	-376	-2.13K	-610	40	17.64K	868	1.49K	-578	142.89K
Cash And Cash Equivalents Changes	-	-	-	-	-	-	-	-824	2.86K	-15.08K	-13.39K
Totals		-7.95K	-4.15K	99.49K	-14.77K	-13.68K	-29.09K	-3.49K	-34.95K	-7.03K	-44.05K	-16.01K	-17.13K	-52.77K	133.38K	15.88K	10.07K	43.49K	-7.51K	-15.76K	-985	32.99K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	Totals
	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	Totals
Cash From Operating Activities	-16.95K	-41.59K	-58.85K	-44.71K	-35.20K	-40.62K	-237.92K
Net Income	-27.45K	-48.61K	-66.76K	-48.69K	27.57K	126.22K	-37.71K
Depreciation	3.62K	4.24K	4.02K	3.99K	4.01K	3.93K	23.82K
Extraordinary Items	-	-	-	-	-	-	-
Change Receivables	-	-	-6.09K	-2.00K	-	-	-8.09K
Change To Inventory	-4.99K	-2.75K	-7.55K	-2.11K	-1.31K	-5.47K	-24.19K
Change To Liabilities	-	-	5.45K	4.24K	-954	1.13K	9.87K
Change To Net Income	-	-	12.15K	7.22K	-59.03K	-166.80K	-206.45K
ChangeToOperatingActivities	-	-	5.60K	874	-3.51K	1.16K	4.12K
Cash flows From Investing Activities	-	-	39.95K	-81.91K	15.59K	-5.87K	-32.24K
Capital Expenditures	-5.44K	-4.81K	-2.39K	-1.94K	-2.54K	-4.09K	-21.21K
Other Cashflows From Investing Activities	-	-	-	-	-	-	-
Cash From Financing Activities	123.32K	61.52K	6.33K	137.34K	25.24K	1.33K	355.08K
Net Borrowings	-	-	-145	14.87K	24.86K	-185	39.40K
Sale Purchase Of Stock	-	-1.42K	-643	121.93K	-	-	119.86K
Dividends Paid	-	-	643	-	-	-	643
Other Cashflows From Financing Activities	-	-4.28K	-1.38K	1.23K	379	1.51K	-2.53K
Cash And Cash Equivalents Changes	-	-	-12.57K	10.73K	-	-	-1.84K
Totals		72.11K	-37.70K	-82.23K	121.07K	-4.89K	-87.75K	-19.39K

Profile

Free Stocks

Company

Features

Contact Us